Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

September 9th 2021

The effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.

Data Confirms Efficacy of Fixed-Volume Isatuximab-Based Combination for Newly Diagnosed Multiple Myeloma

September 9th 2021

The safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone were confirmed for patients with newly diagnosed multiple myeloma with no immediate intent for transplant.

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

September 9th 2021

For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.

Daratumumab Plus Combination Therapy May Be New Standard of Care for Newly Diagnosed Multiple Myeloma

September 9th 2021

Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.

Iberdomide Combination Shows Promise and Tolerability in Multiple Myeloma

September 9th 2021

Iberdomide combined with dexamethasone and either daratumumab, bortezomib, or carfilzomib showed efficacy and tolerability in patients with relapsed or refractory multiple myeloma.

Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma

September 3rd 2021

Frits van Rhee, MD, PhD, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.

Dr. Martin on Key Advances in Multiple Myeloma

August 31st 2021

Thomas G. Martin, MD, discusses recent key advances in multiple myeloma.

Venetoclax Plus Dd and DVd Elicits Deep and Durable Responses in Relapsed/Refractory Multiple Myeloma

August 31st 2021

The addition of venetoclax to daratumumab, bortezomib, and dexamethasone or daratumumab and dexamethasone alone led to a response rate of more than 90% in patients with relapsed/refractory multiple myeloma, which proved durable in the majority of patients, particularly those with t(11;14) translocation.

NICE Recommends Against Daratumumab Combo for Newly Diagnosed Myeloma

August 30th 2021

The United Kingdom’s National Institute for Health and Care Excellence will not recommend daratumumab plus bortezomib, thalidomide, and dexamethasone for use as induction and consolidation treatment in adult patients with untreated multiple myeloma, when an autologous stem cell transplant is suitable.

Dr. Patel on Future Research Directions With CAR T-Cell Therapy in Myeloma

August 24th 2021

Krina K. Patel, MD, MSc, discusses future research directions with CAR T-cell therapy in patients with multiple myeloma.

Investigational Agents for Relapsed/Refractory Myeloma

August 24th 2021

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.

CARTITUDE-1 and CARTITUDE-2 Trials in Multiple Myeloma

August 24th 2021

Multiple myeloma experts evaluate the safety and efficacy of ciltacabtagene autoleucel for RRMM, as seen in updated data presented at ASCO 2021 for the CARTITUDE-1 and CARTITUDE-2 studies.

MRD Negativity Moves Into the Spotlight as a Potential Surrogate End Point in Multiple Myeloma

August 23rd 2021

Ongoing research efforts are pushing to establish minimal residual disease negativity as a surrogate end point for patient outcomes in multiple myeloma clinical trials, and MRD assessment is becoming an increasingly utilized tool to inform real-world clinical decisions.

Dr. Patel on the Potential Utility of Elranatamab in Multiple Myeloma

August 18th 2021

Krina K. Patel, MD, MSc, discusses the potential utility of elranatamab in multiple myeloma.

Using CAR T Therapy for Relapsed/Refractory Myeloma

August 17th 2021

Nina Shah, MD, leads the discussion on the role of CAR T-cell therapy, including idecabtagene vicleucel, for the management of RRMM.

Role of BCMA-Targeted Agents in Myeloma

August 17th 2021

Experts in multiple myeloma review the use of belantamab mafodotin as described in the DREAMM-2 trial and discuss the management of the associated ototoxicity.

FDA Grants CAR T-cell Therapy ALLO-715 Orphan Drug Status for Multiple Myeloma

August 17th 2021

The FDA has granted an orphan drug designation to the allogeneic CAR T-cell therapy ALLO-715 for the treatment of patients with multiple myeloma.

FDA Grants Orphan Drug Designation to CFT7455 for Multiple Myeloma

August 16th 2021

The FDA has granted an orphan drug designation to CFT7455 for use as a potential therapeutic option in patients with multiple myeloma.

Making the Most of Therapeutic Options in Multiple Myeloma

August 13th 2021

Krina K. Patel, MD, MSc, discusses the use of CAR T-cell therapy in multiple myeloma, potential target antigens beyond BCMA, the rich research landscape, and the role of quadruplets and radiation therapy.

Dr. Lee on the Evolving Treatment Paradigm in Relapsed/Refractory Multiple Myeloma

August 10th 2021

Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.